Seguir
Aude I Segaliny
Título
Citado por
Citado por
Ano
Elucidation of Exosome Migration Across the Blood–Brain Barrier Model In Vitro
CC Chen, L Liu, F Ma, CW Wong, XE Guo, JV Chacko, HP Farhoodi, ...
Cellular and molecular bioengineering 9, 509-529, 2016
4822016
Stem cell-derived exosomes as nanotherapeutics for autoimmune and neurodegenerative disorders
M Riazifar, MR Mohammadi, EJ Pone, A Yeri, C Lasser, AI Segaliny, ...
ACS nano 13 (6), 6670-6688, 2019
4452019
Interleukin‐34 promotes tumor progression and metastatic process in osteosarcoma through induction of angiogenesis and macrophage recruitment
AI Ségaliny, A Mohamadi, B Dizier, A Lokajczyk, R Brion, R Lanel, ...
International journal of cancer 137 (1), 73-85, 2015
2012015
Receptor tyrosine kinases: Characterisation, mechanism of action and therapeutic interests for bone cancers
AI Ségaliny, M Tellez-Gabriel, MF Heymann, D Heymann
Journal of bone oncology 4 (1), 1-12, 2015
2002015
Functional TCR T cell screening using single-cell droplet microfluidics
AI Segaliny, G Li, L Kong, C Ren, X Chen, JK Wang, D Baltimore, G Wu, ...
Lab on a Chip 18 (24), 3733-3749, 2018
1702018
The 5A apolipoprotein AI mimetic peptide displays antiinflammatory and antioxidant properties in vivo and in vitro
F Tabet, AT Remaley, AI Segaliny, J Millet, L Yan, S Nakhla, PJ Barter, ...
Arteriosclerosis, thrombosis, and vascular biology 30 (2), 246-252, 2010
1442010
Mechanoresponsive stem cells to target cancer metastases through biophysical cues
L Liu, SX Zhang, W Liao, HP Farhoodi, CW Wong, CC Chen, AI Ségaliny, ...
Science translational medicine 9 (400), eaan2966, 2017
1112017
Syndecan-1 regulates the biological activities of interleukin-34
AI Segaliny, R Brion, E Mortier, M Maillasson, M Cherel, Y Jacques, ...
Biochimica et Biophysica Acta (BBA)-Molecular Cell Research 1853 (5), 1010-1021, 2015
1012015
Preclinical mouse models of osteosarcoma
Ö Uluçkan, A Segaliny, S Botter, JM Santiago, AJ Mutsaers
BoneKEy reports 4, 2015
522015
IL-34 and M-CSF form a novel heteromeric cytokine and regulate the M-CSF receptor activation and localization
AI Ségaliny, R Brion, B Brulin, M Maillasson, C Charrier, S Téletchéa, ...
Cytokine 76 (2), 170-181, 2015
512015
Bone morphogenetic protein 2 and transforming growth factor β1 inhibit the expression of the proinflammatory cytokine IL-34 in rheumatoid arthritis synovial fibroblasts
M Chemel, R Brion, AI Segaliny, A Lamora, C Charrier, B Brulin, ...
The American journal of pathology 187 (1), 156-162, 2017
462017
Combinatorial targeting of cancer bone metastasis using mRNA engineered stem cells
AI Segaliny, JL Cheng, HP Farhoodi, M Toledano, CC Yu, B Tierra, ...
EBioMedicine 45, 39-57, 2019
202019
Stem cell-derived exosomes as nanotherapeutics for autoimmune and neurodegenerative disorders. ACS Nano. 2019; 13 (6): 6670–88
M Riazifar, MR Mohammadi, EJ Pone, A Yeri, C Lässer, AI Segaliny, ...
19
A high throughput bispecific antibody discovery pipeline
AI Segaliny, J Jayaraman, X Chen, J Chong, R Luxon, A Fung, Q Fu, ...
Communications biology 6 (1), 380, 2023
152023
Optimization of a syngeneic murine model of bone metastasis
HP Farhoodi, AI Segaliny, ZW Wagoner, JL Cheng, L Liu, W Zhao
Journal of Bone Oncology 23, 100298, 2020
142020
Anti IL-34 antibodies
D Heymann, A Segaliny, R Brion
US Patent 10,703,813, 2020
32020
BMP-2 and TGF-β1 inhibit the expression of the pro-inflammatory cytokine IL-34 in rheumatoid arthritis synovial fibroblasts
M Chemel, R Brion, A Segaliny, A Lamora, C Charrier, B Brulin, ...
American Journal of Pathology 187 (1), 156–162, 2017
22017
1155 ABS-101, a novel class of tumor-activated CD3xTROP2 T cell engager for solid tumors
Y Zhou, X Ma, X Jiang, R Rivera, R Bettman, JY Chen, TT Aye, A Navarro, ...
Journal for ImmunoTherapy of Cancer 12 (Suppl 2), 2024
2024
Anti-cd3 constructs and uses thereof
Y Shang, AI Segaliny, MA Xiaoya, X Jiang, G Wu
US Patent App. 18/570,578, 2024
2024
10,368 first dates: Microfluidic T cell matchmaking
SH Au
Science Translational Medicine 10 (468), eaav9144, 2018
2018
O sistema não pode executar a operação agora. Tente novamente mais tarde.
Artigos 1–20